论文部分内容阅读
11月11日,公司公布业绩预增提示性公告,称经公司财务部门初步测算,,预计公司2005年1-12月净利润较上年同期大幅上升50%以上。分析师认为现代制药主营产品定位高、盈利能力强,同时大股东医药产品的研发实力雄厚,为公司未来持续快速发展奠定了良好的基石。
November 11, the company announced pre-performance reminder announcement, said the company’s financial department preliminary estimates, the company expects January-December 2005 net profit rose more than 50% over the previous year. Analysts believe that Hyundai Pharmaceutical’s main product positioning is high and its profitability is strong. Meanwhile, the research and development strength of major shareholder pharmaceutical products is strong, laying a good foundation for the company’s sustained and rapid development in the future.